How to buy Cellmid shares
Own Cellmid shares in just a few minutes.
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Cellmid Limited is a biotechnology business based in Australia. Cellmid shares (CDY) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Cellmid has a trailing 12-month revenue of around $6.6 million.
How to buy shares in Cellmid
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the Australian Securities Exchange (ASX). Our table below can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Cellmid. Find the share by name or ticker symbol: CDY. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Cellmid reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check in on your investment. Congratulations, you own a part of Cellmid. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Cellmid share priceUse our graph to track the performance of CDY stocks over time.
Cellmid shares at a glance
|52-week range||$0.083 - $0.385|
|50-day moving average||$0.1029|
|200-day moving average||$0.105|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.078|
Compare share trading platforms
Is it a good time to buy Cellmid stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Cellmid price performance over time
|1 month (2021-03-19)||15.19%|
|5 years (2016-04-16)||inf%|
|Revenue TTM||$6.6 million|
|Gross profit TTM||$4.9 million|
|Return on assets TTM||-32.7%|
|Return on equity TTM||-82.88%|
|Market capitalisation||$11.6 million|
TTM: trailing 12 months
Cellmid share dividends
We're not expecting Cellmid to pay a dividend over the next 12 months.
Have Cellmid's shares ever split?
Cellmid's shares were split on a 1:20 basis on 26 November 2017. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cellmid shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Cellmid shares which in turn could have impacted Cellmid's share price.
Cellmid share price volatility
Over the last 12 months, Cellmid's shares have ranged in value from as little as $0.083 up to $0.385. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Cellmid's is -1.4505. This would suggest that Cellmid's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Cellmid has bucked the trend.
Cellmid Limited, a life sciences company, researches, develops, and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia, the United States, and Japan. The company offers midkine, a driver and modulator of inflammatory diseases, including chronic inflammatory diseases and cancer; and focuses on blocking midkine, a protein for autoimmune disorders, chronic inflammation, osteoporosis, cardiovascular diseases, cancer, and neurodegenerative diseases. It also develops and sells over-the-counter products; and a range of FGF5 inhibitor hair growth products under the evolis, evolis Professional, Lexilis Hybrid, Jo-Ju RED, and Lexilis BLACK brands. In addition, the company sells SARS-CoV-2 antibody kits and PCR tests. It markets its products through retailers and wholesalers, as well as through a direct-to-consumer e-commerce platform. Cellmid Limited was incorporated in 2004 and is based in Sydney, Australia.
Frequently asked questions
More guides on Finder
How to invest in the Didi Chuxing IPO from Australia
Everything we know about the Didi Chuxing IPO, plus information on how to buy in.
How to buy Robinhood stock from Australia
Robinhood is set to go public as soon as June. Here's what you need to do to buy in from Australia.
How to build a DIY Raspberry Pi arcade machine for retro gaming
We explain everything you need to make your own retro arcade machine, built around the super-flexible Raspberry Pi.
International money transfer services
Beat the banks, find the best exchange rates and avoid fees when you send money abroad from Australia.
How to sell shares in Australia
All the key info you need to know to sell shares you inherited or received as a gift.
How to buy Roblox (RBLX) shares from Australia
Steps to owning and managing Roblox shares.
How to invest in the Deliveroo IPO from Australia
Everything we know about the Deliveroo IPO, plus information on how to buy in.
How to buy Cellmid shares
Steps to owning and managing Zebit shares.
Ask an Expert